CSB 4.14(1)(b)
(b) The relevant agency operating the prescription monitoring program agrees to exchange similar information with the program.
CSB 4.14(2)
(2) In determining the compatibility of a prescription monitoring program to the program, the board may consider any of the following:
CSB 4.14(2)(a)
(a) The safeguards for privacy of patient records and the prescription monitoring program's success in protecting patient privacy.
CSB 4.14(2)(b)
(b) The persons authorized to access the information stored by the prescription monitoring program.
CSB 4.14(2)(c)
(c) The schedules of controlled substances monitored by the prescription monitoring program.
CSB 4.14(2)(d)
(d) The information required by the agency to be submitted regarding the dispensing of a prescription drug.
CSB 4.14(2)(e)
(e) The costs and benefits to the board of sharing information.
CSB 4.14(3)
(3) The board may assess a prescription monitoring program's continued compatibility with the program at any time.
CSB 4.14 History
History: CR 12-009: cr.
Register October 2012 No. 682, eff. 1-1-13;
CR 14-003: am. (1) (intro.)
Register August 2014 No. 704, eff. 9-1-14;
EmR1706: emerg. am. (title), (1) (intro.), eff. 4-1-17;
CR 17-028: am. (title), (1) (intro.)
Register December 2017 No. 744, eff. 1-1-18.
CSB 4.15
CSB 4.15
Disclosure of suspicious or critically dangerous conduct or practices. CSB 4.15(1)
(1) The board may review dispensing data, monitored prescription drug history reports, PDMP data, and data compiled pursuant to s.
CSB 4.12 to determine whether circumstances indicate suspicious or critically dangerous conduct or practices of a pharmacist, pharmacy, practitioner, or patient.
CSB 4.15(2)
(2) The board may include any of the following factors when determining whether circumstances indicate suspicious or critically dangerous conduct or practices of a pharmacist or pharmacy:
CSB 4.15(2)(a)
(a) The pharmacist or pharmacy's monitored prescription drug dispensing practices deviate from accepted pharmacist or pharmacy practices.
CSB 4.15(2)(b)
(b) There are unusual patterns in the payment methodology used by patients to whom monitored prescription drugs are dispensed by the pharmacist or pharmacy.
CSB 4.15(2)(c)
(c) The history of actions taken against the pharmacist or pharmacy by other state agencies, agencies of another state, or law enforcement.
CSB 4.15(2)(d)
(d) The type and number of monitored prescription drugs dispensed by the pharmacist or at the pharmacy.
CSB 4.15(2)(e)
(e) The pharmacist or pharmacy has dispensed forged prescription orders for a monitored prescription drug.
CSB 4.15(2)(f)
(f) The distance patients travel to have monitored prescription drugs dispensed at the pharmacy.
CSB 4.15(2)(g)
(g) The number of patients dispensed monitored prescription drugs at the pharmacy or by the pharmacist who satisfy any of the criteria identified in sub.
(4).
CSB 4.15(3)
(3) The board may include any of the following factors when determining whether circumstances indicate suspicious or critically dangerous conduct or practices of a practitioner:
CSB 4.15(3)(a)
(a) The practitioner's monitored prescription drug prescribing practices deviate from accepted prescribing practices.
CSB 4.15(3)(b)
(b) The practitioner prescribes potentially dangerous combinations of monitored prescription drugs to the same patient.
CSB 4.15(3)(c)
(c) The type and number of monitored prescription drugs prescribed by the practitioner.
CSB 4.15(3)(d)
(d) The history of actions taken against the practitioner by other state agencies, agencies of another state, or law enforcement.
CSB 4.15(3)(e)
(e) The distance patients travel to obtain monitored prescription drug prescriptions from the practitioner.
CSB 4.15(3)(f)
(f) The number of patients to whom the practitioner prescribed a monitored prescription who satisfy any of the criteria identified in sub.
(4).
CSB 4.15(4)
(4) The board may include any of the following factors when determining whether circumstances indicate suspicious or critically dangerous conduct or practices of a patient:
CSB 4.15(4)(a)
(a) The number of practitioners from whom the patient has obtained a prescription for a monitored prescription drug.
CSB 4.15(4)(b)
(b) The number of pharmacies from where the patient was dispensed a monitored prescription drug.
CSB 4.15(4)(c)
(c) The number of prescriptions for a monitored prescription drug obtained by the patient.
CSB 4.15(4)(d)
(d) The number of monitored prescription drug doses dispensed to the patient.
CSB 4.15(4)(e)
(e) Whether the monitored prescription drugs dispensed to the patient include dangerous levels of any drug.
CSB 4.15(4)(f)
(f) The number of times the patient is prescribed or dispensed a monitored prescription drug before the previously dispensed amount of the same or a similar monitored prescription drug would be expected to end.
CSB 4.15(4)(g)
(g) The payment methodology used by the patient to obtain controlled substances at a pharmacy.
CSB 4.15(5)
(5) Upon determining that circumstances indicate suspicious or critically dangerous conduct or practices of a pharmacy, practitioner, or patient, the Board may disclose monitored prescription drug history reports, audit trails, and PDMP data to any of the following:
CSB 4.15(6)
(6) Upon determining that a criminal violation may have occurred, the board may refer a pharmacist, pharmacy, or practitioner to the appropriate law enforcement agency for investigation and possible prosecution. The board may disclose monitored prescription drug history reports, audit trails, and PDMP data to the law enforcement agency as part of the referral.
CSB 4.15 History
History: CR 15-101: cr.
Register June 2016 No. 726, eff. 7-1-16;
CR 17-028: am. (1), (5) (intro.), cr. (6)
Register December 2017 No. 744, eff. 1-1-18.
